Cargando…

Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non‐small cell lung cancer

BACKGROUND: There is no consensus on the definition or recommended radiotherapy treatment of ultracentral non‐small cell lung cancer (NSCLC). Here, we report our institution's experience in treating ultracentral lung cancer patients with stereotactic ablative radiotherapy (SABR) of 60 Gy in eig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Dan, Cui, Jianing, Zhao, Jun, You, Jing, Yu, Rong, Yu, Huiming, Jiang, Leilei, Li, Dongming, Xu, Bo, Shi, Anhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049487/ https://www.ncbi.nlm.nih.gov/pubmed/32012484 http://dx.doi.org/10.1111/1759-7714.13335

Ejemplares similares

Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors
por: Zhao, Yizhou, et al.
Publicado: (2020)

Stereotactic body radiotherapy (SBRT) for central and ultracentral node-negative lung tumors
por: Owen, Dawn, et al.
Publicado: (2020)

Ten fraction hypofractionated stereotactic body radiotherapy for the management of ultracentral lung tumors: a retrospective analysis of dosimetry, outcomes, and toxicity
por: Rock, Crosby, et al.
Publicado: (2023)

An optimal dose‐fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early‐stage non‐small lung cancer
por: Zarębska, Izabela, et al.
Publicado: (2023)

Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors
por: Regnery, Sebastian, et al.
Publicado: (2020)

Dose-response relationship of stereotactic body radiotherapy for ultracentral tumor and comparison of efficacy with central tumor: a meta-analysis
por: Rim, Chai Hong, et al.
Publicado: (2020)

Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3)
por: Regnery, Sebastian, et al.
Publicado: (2022)

Stereotactic body radiotherapy for centrally-located lung tumors with 56 Gy in seven fractions: A retrospective study
por: Aoki, Shuri, et al.
Publicado: (2018)

External validation of pulmonary radiotherapy toxicity models for ultracentral lung tumors
por: Chen, Ishita, et al.
Publicado: (2022)

Hypofractionated High-Dose Intensity-Modulated Radiotherapy (60 Gy at 2.5 Gy per Fraction) for Recurrent Renal Cell Carcinoma: A Case Report
por: Cho, Jaeho, et al.
Publicado: (2008)

Comparison of once daily radiotherapy to 60 Gy and twice daily radiotherapy to 45 Gy for limited stage small-cell lung cancer
por: Han, Dan, et al.
Publicado: (2015)

30 GY IN 4 STEREOTACTIC BODY RADIOTHERAPY (SBRT) FRACTIONS FOR COMPLEX SPINAL METASTASES: MATURE OUTCOMES SUPPORTING THIS NOVEL REGIMEN
por: Moore-Palhares, Daniel, et al.
Publicado: (2023)

Stereotactic Ablative Radiotherapy Fractionation for Hepatocellular Carcinoma in the United States
por: Sheth, Niki, et al.
Publicado: (2020)

Prospective In Silico Evaluation of Cone-Beam Computed Tomography-Guided StereoTactic Adaptive Radiation Therapy (CT-STAR) for the Ablative Treatment of Ultracentral Thoracic Disease
por: Schiff, Joshua P., et al.
Publicado: (2023)

Biologically effective doses of 60–70Gy versus >70Gy of stereotactic body radiotherapy (SBRT) combined with chemotherapy in locally advanced pancreatic cancer: protocol of a single-centre, phase II clinical trial
por: Ye, Yusheng, et al.
Publicado: (2022)

Is lung stereotactic ablative radiotherapy safe after pneumonectomy?—a systematic review
por: Arifin, Andrew J., et al.
Publicado: (2020)

Hypofractionated Volumetric-Modulated Arc Radiotherapy for Patients With Non-Small-Cell Lung Cancer Not Suitable for Surgery or Conventional Chemoradiotherapy or SBRT
por: Shen, Junyue, et al.
Publicado: (2021)

Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer
por: Dubaere, Emilie, et al.
Publicado: (2019)

Dose reduction trial from 60 Gy in 10 fractions to 54 Gy in 9 fractions schedule in high-dose-rate interstitial brachytherapy for early oral tongue cancer
por: Akiyama, Hironori, et al.
Publicado: (2012)

Randomized Pilot Study of 20 Gy in 5 Fractions versus 27 Gy in 3 Fractions Radiotherapy for Treating Painful Bone Metastases: A Single Institution Experience
por: Sakr, Amr, et al.
Publicado: (2020)

Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial
por: Henke, Lauren E., et al.
Publicado: (2018)

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy/Hypofractionated Radiation therapy for Metastatic and Primary Central and Ultracentral Lung Lesions
por: Sandoval, Maria L., et al.
Publicado: (2023)

Effects of two different radiotherapies for craniopharyngiomas using stereotactic radiosurgery/ stereotactic radiotherapy or fractionated stereotactic radiotherapy
por: Kamogawa, Misaki, et al.
Publicado: (2022)

Radiotherapy with fraction size of 2.25 Gy in T1-2 laryngeal and hypopharyngeal cancer
por: Karasawa, Kumiko, et al.
Publicado: (2013)

Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions
por: Ermiş, Ekin, et al.
Publicado: (2015)

Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83–100 Gy in five fractions
por: Takeda, Atsuya, et al.
Publicado: (2016)

Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma
por: Webking, Samantha, et al.
Publicado: (2023)

Advances in Radiobiology of Stereotactic Ablative Radiotherapy
por: Qiu, Bin, et al.
Publicado: (2020)

Exceeding Radiation Dose to Volume Parameters for the Proximal Airways with Stereotactic Body Radiation Therapy Is More Likely for Ultracentral Lung Tumors and Associated with Worse Outcome
por: Farrugia, Mark, et al.
Publicado: (2021)

Hypofractionated radiotherapy for early stage glottic cancer: efficacy of 3.5 Gy per fraction
por: Lee, Tae Hoon, et al.
Publicado: (2022)

Doses, fractionations, constraints for stereotactic radiotherapy
por: Borghesi, Simona, et al.
Publicado: (2022)

A retrospective study of sinonasal tumors in 182 dogs treated with stereotactic radiotherapy (3 × 10 Gy) (2010‐2015)
por: Yoshikawa, Hiroto, et al.
Publicado: (2023)

Simulating the Potential of Model-Based Individualized Prescriptions for Ultracentral Lung Tumors
por: Chen, Ishita, et al.
Publicado: (2023)

Stereotactic ablative body radiotherapy versus conventionally fractionated radiotherapy for early stage large cell neuroendocrine carcinoma of the lung
por: Wegner, Rodney E, et al.
Publicado: (2020)

Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume
por: Takeda, Atsuya, et al.
Publicado: (2014)

Elective nodal dose of 60 Gy or 50 Gy in head and neck cancers: A matched pair analysis of outcomes and toxicity
por: Murthy, Vedang, et al.
Publicado: (2017)

The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology
por: Finkelstein, Steven Eric, et al.
Publicado: (2011)

Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver
por: Kim, Myungsoo, et al.
Publicado: (2014)

Adrenal oligometastasis cured with stereotactic ablative radiotherapy
por: Malone, Julia, et al.
Publicado: (2020)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_moka7ocv02hd0io6lc3e3keimt